FlynancialAnalyst Posted - 04/24/24

Dont $CNTA ur chickens, or broken eggs, until u see the wkly close $XBI $NAMS $IMCR $MDGL

Stock_Titan Posted - 04/24/24

$IMCR Immunocore announces upcoming presentation and posters at ASCO 2024 https://www.stocktitan.net/news/IMCR/immunocore-announces-upcoming-presentation-and-posters-at-asco-u27xod2m7eci.html

Night_Owl_Biotech Posted - 04/19/24

The $XBI has technically crashed now that it is down 20% over the last 36 trading days (intra-day). We ran a history of the XBI since launched & noted several other periods where crashes in the XBI have been much worse. Unfortunately, we have no idea how the XBI will trade in the near-term. However, it may, again may, be a better time for patient long-term investors to buy quality commercial-stage biopharmas today than it was 36 trading days ago. Of course these so called quality stocks may fall another 20% over the next 2 months for all we know. $SWTX $IMCR $BCRX $MDGL This is not investment advice. As always, the data on the attachment may be inaccurate. You can lose your entire investment buying biopharma stocks.

Capitulation_0 Posted - 04/19/24

$IMCR close to coming back to this name. rode this from low 40's to 70.. looks very attractive here but will look for reversal signal

dhovekamp42 Posted - 04/19/24

@Apr4609 @MagicPills also noteworthy the comments regarding PRAME TCR with multiple upcoming data from Adaptimmune competitors $IMTX Immatics and former sister company $IMCR Immunocore

dhovekamp42 Posted - 04/19/24

@Rabinovich @Thomasdina if $ADAP will do raise so Mizuho will not be alone - listen to the analyst talking about at the Adaptimmune "investor day" and also PRAME as a TCR target at competitors $IMCR Immunocore and $IMTX Immatics https://x.com/dhovekamp42/status/1781151777687064820

Night_Owl_Biotech Posted - 04/15/24

The attachment notes the share price activity over the last 6 weeks of the 5 (relatively) recent commercial-stage oncology focused biopharmas with FDA approved cancer therapies anticipated to do at least $1B (or very close to $1B/year). All 5 are down 10-20% more or less consistent with the change in the XBI. It's our experience oncology focused biopharmas are more often acquired than non. Of course this does not mean it will be the case in the future. As always, our data could be wrong. This is not investment advice. $IMCR $SWTX $DAWN $DCPH $XBI

dhovekamp42 Posted - 04/12/24

@BioCrEq @Whtmtn $ADAP MAGE A4 CD8+ (Uza-cel) is currently scheduled for next decisions at the end of the year in head & neck / urothelial cancers and a time horizont of 2028 for first approval of Uza-cel in ovarian - PRAME targeting plans will have to wait for the outcome of the front runners $IMCR, $IMTX, and $BNTX

tedevan Posted - 04/07/24

$SNDX $BPMC $IOVA $SWTX $IMCR

Night_Owl_Biotech Posted - 04/07/24

With Morgan Stanley in the news again about M&A & bio valuations with rate cuts, attached is a list of all of the commercial-stage oncology focused bios that have been acquired or merged/spun-off showing the # of months the LLE took place after its last FDA approval (sorted low to high). On the right side please find the remaining independent commercial-stage oncology focused biopharmas noting how long it has been since FDA approval. Be careful, our date info may not be perfect with those that have/had multiple FDA approvals. If commercial-stage oncology focused M&A is expected to be hot this year (versus clinical-stage) then it appears there are only so many with market caps of less than $10B & a recent approval (enough to drive significant growth to an acquirer). Obvious candidates would be $SWTX $IOVA $IMCR $SNDX & $BPMC

Stock_Titan Posted - 04/04/24

$IMCR Immunocore to present at upcoming investor conferences https://www.stocktitan.net/news/IMCR/immunocore-to-present-at-upcoming-investor-za26yd1b4a40.html

dhovekamp42 Posted - 03/23/24

@BiotechJohn Adaptimmune started in 2008 as a collaboration with Carl June on HIV / AIDS and after going public $ADAP developed and co-owns TCR patents with $IMCR in immunmology. I doubt that they currently have the ambition and resources to pick up or add to their huge tasks against cancers.

Thestocktraderhubzee Posted - 03/21/24

$IMCR JP Morgan Maintains Overweight on Immunocore Hldgs, Raises Price Target to $70

Quantumup Posted - 03/21/24

Citi⬆️ $IDYA $60 was $40/rBuy+Top Pick~doesn't believe rally over: +s IDE161 in HRD solid tumors2value; believe further upside will be catalyzed by multi-readouts4daro; reg guide on a pivotal study design; updates from IDE161 Ph1/2/daro 1L MUM pivotal ('24); joint strategy w/ $AMGN $imcr $tngx $bmy

FlynancialAnalyst Posted - 03/19/24

$IMCR rinsed into 40 wk SMA. Institutional ownership has been steadily rising for 2 years straight $XBI $IWM

nycpupster Posted - 03/18/24

$IMCR just trading in it's range, will be back to $78 in no time

nycpupster Posted - 03/15/24

$IMCR taking a swing at this. If it doesn't follow the trendline, it might fall to support around $52-ish, but I think selling is now close to overdone

Quantumup Posted - 03/08/24

BTIG🏁 $IDYA Buy/$55~Co has a robust pipeline of FiC molecules in onc mkts + Strong Balance Sheet. Daro' has shown +VE clin data in the untapped HLA-A2(-) uveal melanoma pt pop, who are ineligible for tx w/ $IMCR 's Buy/$91) KIMMTRAK; +VE'ly views IDE397 as differentiated/pot BiC. $amgn $bmy $tngx

Capitulation_0 Posted - 03/05/24

$VKTX all these CEOs want to become a BP. $IMCR, $CYTK.

Stock_Titan Posted - 2 months ago

$IMCR Immunocore to present at upcoming investor conferences https://www.stocktitan.net/news/IMCR/immunocore-to-present-at-upcoming-investor-1sryv8dqdp8g.html

erevnon Posted - 02/29/24

Needham reiterates Immunocore Hldgs $IMCR at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

Stock_Titan Posted - 02/28/24

$IMCR Immunocore reports fourth quarter and full year 2023 financial results and provides a business update https://www.stocktitan.net/news/IMCR/immunocore-reports-fourth-quarter-and-full-year-2023-financial-48lf6b72vp1x.html

techj2022 Posted - 02/24/24

$IMTX PRAME is a validated target. its pipeline looks very promising. weekly candle looks highly constructive. needs to break 13 for a breakout. expect valuation gap with $imcr to narrow.

GPS_OS_21_vs_SOC_5 Posted - 02/22/24

$SLS $IMCR

DonCorleone77 Posted - 02/22/24

$IMCR Immunocore enters trial collaboration, supply agreement with Bristol Myers Immunocore Holdings (IMCR) announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMY) to investigate Immunocore's ImmTAC bispecific TCR candidate targeting PRAME HLA-A02, IMC-F106C, in combination with Bristol Myers Squibb's nivolumab, in first-line advanced cutaneous melanoma. Under the terms of the collaboration, Immunocore will sponsor and fund the registrational Phase 3 clinical trial of IMC-F106C in combination with nivolumab in first-line advanced cutaneous melanoma, and Bristol Myers Squibb will provide nivolumab.

Stock_Titan Posted - 02/22/24

$IMCR Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial https://www.stocktitan.net/news/IMCR/immunocore-announces-clinical-trial-collaboration-and-supply-ynqz8fp72dze.html

Stock_Titan Posted - 02/21/24

$IMCR Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024 https://www.stocktitan.net/news/IMCR/immunocore-to-report-fourth-quarter-and-full-year-2023-financial-itvi17tl32if.html

swingingtech Posted - 02/19/24

$SRPT $RHHBY $ADMA $IMCR https://wallstreetwaves.com/sareptas-srpt-dmd-drug-sbla-gets-fdas-priority-tag-stock-up/

techj2022 Posted - 02/12/24

$IMTX bullish cup w handle on weekly. only one of 2 bios targeting PRAME, the other one is $IMCR

rachelstocks Posted - 02/10/24

$IMCR listened to last earnings call. Super bullish